Clinical bottom line
Combination therapies for advanced hepatocellular carcinoma (HCC) have emerged as a promising approach to improve outcomes. Recent studies suggest that combining immune checkpoint inhibitors with targeted therapies can enhance survival rates and disease control compared to monotherapies. However, the optimal combination and patient selection criteria remain areas of ongoing research.
What the evidence shows
Recent clinical trials have demonstrated the potential benefits of combination therapies in advanced HCC. Atezolizumab combined with bevacizumab has shown significant improvements in overall survival and progression-free survival compared to sorafenib, the previous standard of care. In the IMbrave150 trial (2020), the combination therapy resulted in a median overall survival of 19.2 months versus 13.4 months with sorafenib (PMID: 32402160).
Additionally, the combination of lenvatinib and pembrolizumab has been investigated in the LEAP-002 trial, showing promising results in terms of response rates and disease control, although final survival data are pending (PMID: 34620443).
These studies highlight the potential of combination therapies to enhance the efficacy of treatment in advanced HCC, offering new hope for improved patient outcomes.
Caveats and uncertainty
While combination therapies show promise, several uncertainties and challenges remain. The optimal selection of patients who would benefit most from these therapies is not fully understood. Biomarkers for predicting response to combination treatments are still under investigation.
Furthermore, combination therapies can lead to increased toxicity. The IMbrave150 trial reported higher rates of hypertension and proteinuria with atezolizumab and bevacizumab compared to sorafenib. Managing these adverse effects is crucial to ensure patient safety and adherence to treatment.
The long-term benefits and potential resistance mechanisms associated with combination therapies are also areas requiring further research. Ongoing trials and real-world studies will help clarify these uncertainties.
How this may change practice
The integration of combination therapies into clinical practice for advanced HCC represents a significant shift in treatment paradigms. These therapies offer the potential for improved survival and disease control, making them a compelling option for eligible patients.
Clinicians should remain informed about the latest evidence and guidelines to make informed decisions regarding the use of combination therapies. Multidisciplinary collaboration is essential to optimize patient selection and manage treatment-related toxicities effectively.
As more data become available, combination therapies may become a standard component of advanced HCC management, potentially improving outcomes for a broader range of patients.